Pharma channel feed – Endpoints News

Pharma channel feed

Amgen loses its bid to delay biosimilars as SCOTUS hands Novartis a victory

8 years ago

Little Dragonfly bursts onto the I/O scene with a $33M Celgene deal and some of the biggest names in biotech

8 years ago

Coherus craters after Amgen wins reprieve on Neulasta knockoff — FDA rejects marketing application

8 years ago

Merck cautiously steps into the PD-(L)1/CTLA-4 checkpoint fray. But should it ‘go big or go home’ instead?

8 years ago

New Chinese VC leads $10M round for a Harvard spinout looking to industrialize platelet manufacturing

8 years ago

Hunting new deals, Eli Lilly buddies up on diabetes R&D with $55M pact

8 years ago

Genentech axes its $1B-plus IDO drug deal with NewLink in the wake of underwhelming data

8 years ago

President Trump asks Francis Collins to stay on at the NIH, sparking bipartisan applause

8 years ago

Ramaswamy notches his 5th biotech startup in 3 years after inking a deal with Merck for PhIII urology drug

8 years ago

July 12 FDA panel review looms as a watershed moment in Novartis’ campaign to win an historic new drug OK

8 years ago

AMRI fetches $922M in the latest CRO private equity buyout

8 years ago

Innate Pharma moves on from a trial disaster with a €40M in-licensing pact with Novo Nordisk

8 years ago

PD-L1 checkpoint player Merck KGaA dives into next-gen work with F-star collaboration

8 years ago

A LAG-3, Opdivo combo from Bristol-Myers offers a proof-of-concept glimpse of limited success

8 years ago

Takeda-backed Mersana joins the biotech IPO queue with a $75M offering and ambitious plans for ADC tech

8 years ago

Endocyte slashes staff and retrenches in the wake of back-to-back R&D setbacks

8 years ago

Checkpoint combos for cancer are all the rage as trial sponsors line up hundreds of new studies — report

8 years ago

ViiV, GSK gamble a surprise $130M chip in a high-stakes HIV playoff with Gilead

8 years ago

Leerink spotlights Novartis’ late-stage stars plus one utility player — suggesting where it could make deals

8 years ago

New report heralds a revolution in cancer R&D trends - and the sticker shock that comes with it

8 years ago

Akari CEO abruptly resigns as a special committee moves a PhII patient success into the fail column

8 years ago

Another old, cheap generic is being prepped for an FDA application — made over into a ‘new’ drug for ADHD and narcolepsy

8 years ago

Medicare drug rebates reward industry players — and often hurt patients

8 years ago

Gilead racing to FDA with a new HIV cocktail boasting megablockbuster potential

8 years ago

First page Previous page 321 322 323324325 326 327 Next page Last page